BioEdge Research Labs, LLC has announced the availability of TB-500 (TB4), now in stock as a 10mg lyophilized reference material for laboratory research use only. Each lot is reviewed for identity and purity before release and is documented through a per-batch Certificate of Analysis (COA) tied to a verifiable lot number.
The TB-500 material is sourced from US manufacturers that follow GMP protocols and is lyophilized domestically. Each vial contains 10mg of freeze-dried peptide and is supplied to qualified research institutions and laboratories conducting peptide studies. The material is presented strictly as a research reference compound for in vitro and other laboratory applications, not as a consumer-facing product.
TB-500 (CAS 77591-33-4) is a synthetic peptide related to a fragment of thymosin beta-4, a naturally occurring protein segment frequently referenced in peptide research discussions. In laboratory settings it is defined by its amino acid sequence and its characteristic analytical profile, and its identity is typically confirmed by comparing observed mass and chromatographic behavior against the expected values for the known sequence. Across current online search results, TB-500 appears widely in informal "stack" descriptions — often grouped with BPC-157 in pages describing "Glow," "Wolverine," or similar combinations — but this terminology is marketing shorthand and is not part of standardized scientific nomenclature. BioEdge uses "TB-500 (TB4)" only as a catalog descriptor for a defined research reference material, and does not present the term as a clinical protocol, treatment category, or approved formulation.
Every lot of BioEdge TB-500 undergoes a 7-point testing protocol carried out by an independent third-party laboratory, with multiple vials sampled from each lot and reported individually alongside the batch average rather than relying on a single representative unit. The panel covers purity by reversed-phase high-performance liquid chromatography (RP-HPLC; C18 column, DAD detection at 214 nm), verified against a specification of greater than 98 percent; net peptide content; identity confirmation by liquid chromatography–mass spectrometry (LC-MS); an endotoxin safety screen by Limulus Amebocyte Lysate (LAL) assay to a limit of 0.5 EU/mL or lower; a fentanyl presence analysis; a microbial sterility screen; and heavy-metal screening for arsenic, cadmium, lead, and mercury. This same panel is applied to every BioEdge product. The results form the lot-release criteria: only batches that meet every specification across all sampled vials move forward to packaging and distribution under their assigned lot numbers.
Each stocked lot is a distinct batch and is issued its own certificate rather than sharing documentation across production runs. Each vial carries a lot number matched to the COA for that specific batch, and that number can be checked against the testing laboratory's own records as well as the copy posted on the BioEdge product page. Because the analytical record sits with the independent laboratory rather than only with the supplier, a research buyer can confirm what is in a given vial without relying on the supplier's word — a point of particular value for procurement review, repeat ordering, and internal recordkeeping.
TB-500 is supplied for research use only. It is not a drug, dietary supplement, or medical product, and it is not marketed with dosing, reconstitution, administration, or treatment guidance. It is not intended to diagnose, treat, cure, or prevent any disease, is not intended to affect the structure or any function of the body, and is not intended for human or veterinary use, consumption, or self-administration. In anti-doping contexts, thymosin beta-4 — the protein to which TB-500 is related — is addressed on prohibited-substance lists, and TB-500 is not approved for human clinical use; BioEdge supplies the compound solely for lawful laboratory research under appropriate oversight.
"Every stocked lot is a distinct batch with its own certificate, backed by a documented multi-point, multi-vial testing protocol," said Dr. Noreen Sherazi, Medical Writer and Research Contributor at BioEdge Research Labs. "What matters for a research buyer is traceability — being able to pull the lot number and confirm the identity, purity, and endotoxin results for the exact vial on the bench, against the independent lab's records rather than the supplier's."
To verify a specific lot, a researcher should read the lot number printed on the vial label, retrieve the matching COA from the BioEdge product page, confirm that the lot number on the certificate matches the vial exactly, and then review the identity, purity, endotoxin, sterility, and screening results along with the testing date. This lets the laboratory move from a product name on a catalog page to a batch-specific analytical record that can be checked, filed, and reviewed before use.
BioEdge Research Labs, LLC specializes in supplying high-purity research peptides and compounds to the scientific research community, and has been recognized for its excellent customer service and high-quality products. All materials are produced by US manufacturers that follow GMP protocols, lyophilized domestically, and verified through independent third-party testing, with per-batch Certificates of Analysis tied to lot numbers. The company serves research institutions throughout the United States and maintains a comprehensive catalog of research-grade reference materials. Researchers can access product documentation and place orders through the company's research portal at https://bioedgeresearchlabs.com.
TB-500 (TB4) 10mg is in stock and available now for immediate shipment to qualified research facilities, with same-day shipping on orders placed before 3PM EST and free shipping on domestic orders over $150. Current specifications, batch testing information, Certificates of Analysis, and pricing are listed on the product page: https://bioedgeresearchlabs.com/product/tb-500-10mg/.
All products referenced are for laboratory research use only. They are not intended for human or veterinary use, or for use in diagnostic procedures, and are not intended to affect the structure or any function of the body. These products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. BioEdge Research Labs is a chemical supplier and is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. BioEdge Research Labs makes no therapeutic claims.
###
For more information about BioEdge Research Labs, LLC, contact the company here:
BioEdge Research Labs
BioEdge Research Labs
(307) 667-1404
info@bioedgeresearchlabs.com
1603 Capitol Ave.
Suite 413-D239,
Cheyenne, WY
